Meeting
2014 ASCO Annual Meeting
Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) in a randomized trial (RCT) compared to a case-control matched British Columbia (BC) breast cancer population.
Authors
Sheridan Marie Wilson
BC Cancer Agency, Vancouver, BC, Canada
Sheridan Marie Wilson , Yvonne Zheng , Judy-Anne W. Chapman , Margot J. Burnell , Caroline Speers , Emily Baxter , Scott Tyldesley , Lois E. Shepherd , Karen A. Gelmon , Caroline A. Lohrisch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1037)
DOI
10.1200/jco.2014.32.15_suppl.1037
Abstract #
1037
Poster Bd #
130
Abstract Disclosures
Similar Posters
Poster
2011 Breast Cancer Symposium
Effect of oral cyclophosphamide use on pathologic complete response rate in the neoadjuvant treatment of breast cancer.
First Author: M. Luque
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2014 ASCO Annual Meeting
Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy.
First Author: Joyce O'Shaughnessy
Poster
2014 ASCO Annual Meeting
Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.
First Author: Federico Rojo